Follow Up for Gynaecological Cancers
Table of Contents

1.0 Background ......................................................................................................................... 3
2.0 Proposal ............................................................................................................................... 4
  2.1 The minimum standard routine clinic review regime would be as follows: .................... 4
  2.2 Exceptions: ....................................................................................................................... 5
      2.2.1 Very Low Risk Patients .......................................................................................... 5
      2.2.2 Other carcinoma of the cervix .............................................................................. 6
      2.2.3 Clinical Trials ......................................................................................................... 6
      2.2.4 Disease and Treatment Related Morbidity ......................................................... 6
      2.2.5 Patient Concerns including Psychosexual Advice ............................................. 6
3.0 Revision History .................................................................................................................... 7
GYNAECOLOGICAL CANCER FOLLOW-UP

Guidelines

1.0 Background

Traditionally, gynaecological cancer patients are followed on a regular clinical review schedule in outpatient clinics, generally for a period of 5 years. Follow-up regimes vary across Kent & Medway, but generally involve regular review on a 3 – 4 monthly basis during the first 2 years, followed by 6 monthly or annual review to a total of 5 years. In most places within the region, follow-up is uncoordinated between different disciplines of the multi-disciplinary teams. Some patients are seen regularly in cancer unit follow-up clinics, cancer centre gynaecological follow-up clinics and clinical oncology follow-up clinics, producing a large number of uncoordinated visits to various hospitals.

Cancer follow-up has been addressed by clinicians in other cancer site specialities, and there are a number of publications which questioned the value of regular follow-up for gynaecological oncology patients. British publications in follow-up in endometrial, cervical and vulval carcinoma have suggested there may be little or no benefit from regular follow-up. It has also been suggested that regular routine clinic follow-up may even be harmful for patients in terms of delaying their presentation for review at the onset of symptoms suggesting possible recurrence and also in terms of anxiety caused by attendance in the clinic. Unfortunately there is no high quality evidence as to the value of follow-up in gynaecological oncology. A multi-disciplinary multi-centre research proposal to assess the value of follow-up in comparison to patient initiated follow-up, in the form of a large randomised control trial, has unfortunately failed to obtain the necessary funding. Several local clinical trials are presently being run within the United Kingdom to assess innovative forms of follow-up but in the absence of the power required to identify benefit of one form or the other in terms of survival, detection of recurrence or quality of life, these studies perhaps should best be viewed as feasibility and acceptability studies for alternative forms of follow-up.

The alternative model of follow-up proposed in these studies is a patient initiated follow-up, in which detailed patient information is provided at an “exit” interview at the end of the episode of care (i.e. the clinic visit shortly following the completion of surgery, chemotherapy or radiotherapy). This consultation and the accompanying written information aims to educate the patient regarding symptoms suggestive of possible disease recurrence. She is given contact details to a nurse specialist and is encouraged to telephone at any time to discuss any concerns she may have regarding symptoms suggestive of recurrent disease or potential treatment related side effects. In response to a call from the patient, the nurse specialist triages the patient appropriately, for urgent review by clinicians in a follow-up clinic, to the general practitioner, to a specialist service such as a lymphoedema clinic, or perhaps initially lists the patient for discussion in the multi-disciplinary team meeting. This model of care appears very attractive as it empowers patients and enables them to access care at short notice when required. It also helps patients to progress beyond the “sick role” as soon as they have recovered from treatment. Unfortunately, at the present time, effectiveness of this model remains unproven.

The following purposes of follow-up were discussed and agreed via the Tumour Site Specific Group (TSSG) and subsequently the Non-Surgical Oncological Group (NOG)

1) Detection of disease recurrence:

The intention is that regular clinic follow-up may enable early detection of disease recurrence. Depending on the disease site, stage and previous treatment, early detection of recurrence may improve the chance of salvage (ie disease cure). It was generally acknowledged that disease recurrence beyond 3 years post treatment is extremely uncommon in any gynaecological oncology disease sites.
2) **Symptom management:**

Gynaecological cancer follow-up clinics enable expert management of symptoms associated with treatment side effects as well as symptoms of active disease.

3) **Patient reassurance:**

Some patients definitely feel that they benefit from regular “check-up” and are reassured when no evidence of recurrent disease is identified. Clearly, however, another group of patients appear to be psychologically harmed by follow-up, developing very real anxiety during the days and weeks preceding clinic appointments.

4) **Outcome Data:**

Regular review in follow-up clinics enables accurate outcome data to be measured. However, documentation of gynae oncology patient status on a cancer database is not presently performed on a routine basis anywhere within the network.

5) **Benefit to clinicians:**

It was widely acknowledged that oncology clinicians benefit from reviewing successfully treated patients in clinic. These patients “brighten” oncology clinics. Trainees also benefit from seeing living proof of effective cancer treatments.

It was acknowledged that the advent of the clinical nurse specialist within gynaecological oncology teams has provided a resource which until several years ago was unavailable within Kent. Most patients develop a relationship with the clinical nurse specialist before and during their period of treatment and therefore find the nurse specialist to be a very appealing link with the clinical team. It was agreed that this resource needs to be harnessed and incorporated into management guidelines for gynae oncology patients within the network.

2.0 **Proposal**

It was agreed by the TSSG that at the present time, in the absence of quality evidence, we should not dispense with the strategy of routine regular follow-up clinic reviews for the majority of gynaecological oncology patients. Instead, it is proposed to rationalize the schedule of routine clinic reviews, and supplement this with an integrated model of patient initiated follow-up, along the lines described above. Each patient would carry a care diary in which the nurse specialist or clinician would clearly document the proposed follow-up protocol.

2.1 **The minimum standard routine clinic review regime would be as follows:**

**Endometrial**

1. Adjuvant stage 1 and 2. Discharge to surgical follow up  
   NOTE: post TAH patients who have MDM recommendation for further nodal surgery or consideration of radiotherapy AND decline both imaging at 6 mths and 18 mths post operative, unless clinical indication for earlier.
2. Stage 3c1:  
   - 1 year follow up CT  
   - 2 year follow up CT  
3. Stage 4 clinical follow up as felt appropriate
Cervical

Primary Surgery:
MRI – at 6 months post-surgical treatment

Primary Chemo-radiotherapy:
Alternate oncology follow up with surgical follow up

Follow up Imaging:
1. Patients with minimal/ no residual tumour on MRI at week 5 of chemoradiotherapy. Consider follow up MRI at 3-4 months post Chemo -Radiotherapy
2. Patients with significant residual tumour on MRI scan at week 5 of chemoradiotherapy. Follow up MRI and PET Scan to be done 3 months from last brachytherapy insertion, prebook date for hysterectomy 4 months from last brachytherapy insertion (pending results of follow up scans and MDM discussion).

Ovary
1. Disease free post adjuvant, 3- 6 monthly alternate oncology/surgical follow up. Individual clinician based guided by clinical history examination and CA125 as felt clinically appropriate
2. Disease present – as per clinical guidelines for follow up
3. Aim alternate oncology and surgical follow up

Initial post treatment clinic review (eg 6 weeks post-op, post chemotherapy) Patients may need to attend each of these in turn.
6 months post-completion of treatment.
12 months post-completion of treatment.
18 months post-completion of treatment.
30 months post-completion of treatment.
42 months post-completion of treatment.

Where patients have undergone treatment by more than one speciality (eg surgery and chemotherapy), the routine scheduled clinic appointments will generally alternate between follow-up clinics. Ideally, multi-disciplinary follow-up clinics will be established and patients will be reviewed within these joint clinics at every visit.

A formalized patient information interview would be held at the end of treatment, at the post treatment clinic appointment if not before. Formalized disease specific patient information would be provided at this time, with contact details for the nurse specialist, to be used in the event of disease or treatment related concerns or symptoms. A nurse specialist would be able to arrange for the patient to be reviewed at any time on an urgent basis in a follow-up clinic when required, in addition to the standard regime as described.

2.2 Exceptions:

2.2.1 Very Low Risk Patients
It was agreed by the gynaecology GNAT that the following specific patient groups do not require any structured routine clinic reviews beyond the initial post treatment appointment. Disease recurrence in these particular patient groups is so rare, it was agreed that integration of these patients into long
Term routine follow-up is perhaps more likely to be harmful than beneficial, causing unnecessary anxiety and prolongation of the "sick role".

1) Endometrial cancer FIGO stage 1A grade 1/grade 2

2) Adequately staged FIGO stage 1 ovarian tumours of borderline malignant potential.
   - These 2 groups should be managed with patient initiated follow-up alone.

3) Carcinoma of the cervix, FIGO stage 1A1
   - These patients should be managed as per high grade CIN under the NHS CSP cytology guidelines.

**2.2.2 Other carcinoma of the cervix**

1) Carcinoma of the cervix.
   - MR at 6/12 post radical surgery/chemo-radiation

**2.2.3 Clinical Trials**

Patients involved in clinical research and trials should undergo follow-up as prescribed by the trial protocol. They should also be offered “patient initiated follow-up” as described above, unless it contravenes the trial protocol.

**2.2.4 Disease and Treatment Related Morbidity**

Review in follow-up clinic will remain available on a basis of need. In addition to patient initiated review, more frequent review can be initiated by any members of the multi-disciplinary team on the basis of need. For example, patients with treatment-related morbidity may require frequent regular review in a follow-up clinic, and would therefore deviate from the standard protocol described above.

**2.2.5 Patient Concerns including Psychosexual Advice**

It is widely recognised that an amount of Follow Up should be delivered by the CNS Team. This allows for issues to be discussed/dealt with that would not otherwise as easily be addressed. This includes psychosexual issues as a result of treatment.
### 3.0 Revision History

<table>
<thead>
<tr>
<th>Document Title</th>
<th>Follow up for Gynaecological Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Principal author(s)</td>
<td>A.Nordin/A.Papadopoulos</td>
</tr>
<tr>
<td>Co-author(s)</td>
<td>N.Aluwalia/J.Kaur</td>
</tr>
<tr>
<td>Current version number</td>
<td>2.0</td>
</tr>
<tr>
<td>Current status</td>
<td>Final</td>
</tr>
<tr>
<td>Original publication date</td>
<td>Mar 2009</td>
</tr>
<tr>
<td>Expected review date by</td>
<td>September 2019</td>
</tr>
</tbody>
</table>

#### Enquiries:
- Andy Nordin
  Consultant Gynae Oncologist
- Steve Montalto
  Consultant Gynae Oncologist
- Elias Kavoor
  Consultant Gynaecologist
- Hany Habeeb
  Consultant Gynaecologist

#### Revision History

<table>
<thead>
<tr>
<th>Date of revision</th>
<th>New Version Number</th>
<th>Nature of Revision</th>
<th>Confirmation of Accuracy by</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov 2005</td>
<td>0.1</td>
<td>Development of Consultation Document</td>
<td>Andy Nordin/GNAT</td>
</tr>
<tr>
<td>Dec 2005</td>
<td>1.0</td>
<td>Amendments following consultation</td>
<td>Gynae DOG</td>
</tr>
<tr>
<td>Nov 2009</td>
<td>1.0</td>
<td>Format change in light of FU guidelines removal from individual PoC. No changes to guidelines</td>
<td>Gynae DOG</td>
</tr>
<tr>
<td>April 2016</td>
<td>1.1</td>
<td>Amendments noted following consultation with CNS’ and review of all content</td>
<td>A.Papdopoulos</td>
</tr>
<tr>
<td>February 2017</td>
<td>1.2</td>
<td>NOG agreed follow up for low risk patients added, to be agreed at the TSSG</td>
<td>N.Aluwalia/J.Kaur/A.Papadopoulos</td>
</tr>
<tr>
<td>September 2017</td>
<td>2.0</td>
<td>Final published document following ratification by O&amp;Q Group</td>
<td></td>
</tr>
</tbody>
</table>

KMCC Gynae Follow Up Guidelines Final September 2017  Page 7 of 7